Clinical Trial Update: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 2 long-term safety, tolerability and efficacy study of AFQ056 (mavoglurant) in adults with Fragile X Syndrome, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fragile X Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-05-25